Author details
Author F.J. Branicki |
Available item(s) by this author (1)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections / NS Jr. Navarro in International journal of surgery, 3(2005)1 ([01/01/2005])
[article] Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections [printed text] / NS Jr. Navarro, Author ; M.I. Campos, Author ; R. Alvarado, Author ; N. Quintero, Author ; F.J. Branicki, Author ; J. Wei, Author ; M. Shivaprakash, Author ; France Vrijens , Author ; H. Giezek, Author ; C.Y. Chan, Author ; M.J. DiNubile, Author . - 2005 . - 25-34.
Languages : English (eng)
in International journal of surgery > 3(2005)1 [01/01/2005] . - 25-34
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Ceftriaxone ; England ; Journal Article ; Metronidazole ; Peer ReviewAbstract: BACKGROUND: Prompt surgical intervention supplemented by appropriate antimicrobial therapy is usually required for successful treatment of complicated intra-abdominal infections. The objective of this study was to further evaluate the efficacy and safety of ertapenem relative to ceftriaxone/metronidazole as treatment for complicated intra-abdominal infections.
METHODS: Adult patients with intra-abdominal infections requiring surgery were eligible for this open-label randomized trial comparing ertapenem 1 g daily with ceftriaxone 2 g daily plus metronidazole 30 mg/kg/day. The primary efficacy outcome was the clinical response rate in clinically and microbiologically evaluable participants at the test-of-cure (TOC) visit 2 weeks after discontinuation of therapy. All treated patients were included in the safety analysis.
RESULTS: Participant demographics, disease characteristics, and duration of therapy in both treatment groups were generally similar. Escherichia coli was the most commonly isolated baseline pathogen, recovered in 52% of cases in each treatment group. Favorable clinical responses were achieved at TOC in 143 (96.6%) of 148 ertapenem recipients and in 146 (96.7%) of 151 ceftriaxone/metronidazole recipients. The frequencies of drug-related adverse events, most commonly nausea, diarrhea, vomiting, and elevated platelet count, were generally comparable in both treatment arms. Four ertapenem recipients (1.8%) and one ceftriaxone/metronidazole recipient (0.4%) experienced serious drug-related adverse events.
CONCLUSIONS: In this study, ertapenem and ceftriaxone/metronidazole were comparably effective treatments for adult patients with complicated intra-abdominal infections.Link for e-copy: http://tiny.cc/9qonk Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2507 [article]